DRK Krankenhaus Neuwied, Neuwied, Germany.
Ann Intern Med. 2010 Dec 7;153(11):710-7. doi: 10.7326/0003-4819-153-11-201012070-00004.
Whipple disease, which is caused by infection with Tropheryma whipplei, can be treated effectively with antimicrobials. Occasionally, inflammation reappears after initial improvement; this is often interpreted as refractory or recurrent disease. However, polymerase chain reaction for T. whipplei in tissue is sometimes negative during reinflammation, indicating absence of vital bacteria, and this reinflammation does not respond to antimicrobials but does respond to steroids.
To demonstrate that the immune reconstitution inflammatory syndrome (IRIS) occurs in patients treated for Whipple disease.
Cohort study. (International Standard Randomised Controlled Trial Number Register registration number: ISRCTN45658456)
2 academic medical centers in Germany.
142 patients treated for Whipple disease out of a cohort of 187 were observed for reappearance of inflammatory signs after effective antibiotic therapy. Definitions of IRIS in HIV infection, tuberculosis, and leprosy were adapted for application to Whipple disease.
On the basis of study definitions, IRIS was diagnosed in 15 of 142 patients. Symptoms included fever, arthritis, pleurisy, erythema nodosum, inflammatory orbitopathy, small-bowel perforation, and a hypothalamic syndrome. Two patients died. There was a positive correlation with previous immunosuppressive treatment and a negative correlation with previous diarrhea and weight loss.
The study was observational and thus has inherent weaknesses, such as incomplete and potentially selective data recording.
The immune reconstitution inflammatory syndrome was diagnosed in about 10% of patients with Whipple disease in the study cohort; the outcome varied from mild to fatal. Patients who had had previous immunosuppressive therapy were at particular risk. An immune reconstitution syndrome should be considered in patients with Whipple disease in whom inflammatory symptoms recur after effective treatment. Early diagnosis and treatment with steroids may be beneficial; prospective studies are needed.
European Commission and Deutsche Forschungsgemeinschaft.
由屈莱弗勒氏疏螺旋体(Tropheryma whipplei)感染引起的惠普尔病可用抗生素有效治疗。偶尔,初始改善后炎症会再次出现;这通常被解释为难治性或复发性疾病。然而,在再次炎症期间,组织中屈莱弗勒氏疏螺旋体的聚合酶链反应有时为阴性,表明不存在有活力的细菌,这种再炎症对抗生素没有反应,但对类固醇有反应。
证明免疫重建炎症综合征(IRIS)发生在接受惠普尔病治疗的患者中。
队列研究。(国际标准随机对照试验注册号:ISRCTN45658456)
德国的 2 所学术医疗中心。
在 187 例接受惠普尔病治疗的患者中,观察 142 例患者在有效抗生素治疗后炎症迹象再次出现的情况。对 HIV 感染、结核病和麻风病中的 IRIS 定义进行了调整,以适用于惠普尔病。
根据研究定义,142 例患者中有 15 例诊断为 IRIS。症状包括发热、关节炎、胸膜炎、结节性红斑、炎症性眼肌病、小肠穿孔和下丘脑综合征。有 2 例患者死亡。与先前的免疫抑制治疗呈正相关,与先前的腹泻和体重减轻呈负相关。
该研究为观察性研究,因此存在固有弱点,例如数据记录不完整和可能具有选择性。
在研究队列中,约 10%的惠普尔病患者被诊断为免疫重建炎症综合征;结局从轻度到致命不等。曾接受过免疫抑制治疗的患者风险特别高。对于有效治疗后炎症症状再次出现的惠普尔病患者,应考虑免疫重建综合征。早期诊断和类固醇治疗可能有益;需要前瞻性研究。
欧盟委员会和德国研究基金会。